An endurant iis stent graft system was implanted during the endovascular treatment of a 57mm abdominal aortic aneurysm. it was reported that during the index procedure, the bifurcate esbf3214c103e (sn:(b)(6)) was deployed per ifu until the contrala teral gate opened.The contralateral gate marker appeared to be compressed.Attempts to cannulate the contralateral gate were made using multiple catheters with no success.The decision was made to complete the deployment of the esbf3214c103e (sn:(b)(6)).The delivery system was recaptured and removed.Utilizing a marker pigtail catheter, the length limb needed on the ipsilateral side was determined.A etlw1616c93e (sn (b)(6)) limb was deployed extending from the esbf3214c103e (sn:(b)(6)) ipsilateral gate into the common right iliac artery.The delivery system was recaptured and removed.Attempting to pass a non-medtronic guidewire (glidewire) from the ipsilateral side up and over the flow divider of the esbf3214c103e (sn:(b)(6)) was made without success.The decision was made to implant a etuf3214c102e (sn: (b)(6)) via the ipsilateral access.The etuf3214c102e (sn: (b)(6)) was deployed, recaptured and removed.A non-medtronic embolization plus (amplatzer plug ii) was implanted via the contralateral access in the left common iliac artery.A completion angiogram via the ipsilateral access was performed.A fem-fem bypass was then performed successfully.Per the physician, the cause of the event is due to patient's anatomy.There was an abdominal defect present that compressed the contralateral gate upon deployment. no additional sequelae was reported and the patient is fine.
|
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|